argenx SE (ARGX) P/E Ratio History
Fairly ValuedTrading at 44.7x, near 5Y avg of 51.9x · 67th percentile · In line with own history · Data 2024–2025
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, argenx SE (ARGX) trades at a price-to-earnings ratio of 44.7x, with a stock price of $877.72 and trailing twelve-month earnings per share of $21.82.
The current P/E is 14% below its 5-year average of 51.9x. Over the past five years, ARGX's P/E has ranged from a low of 26.9x to a high of 92.2x, placing the current valuation at the 67th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, ARGX trades at a 102% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, ARGX commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ARGX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ARGX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ARGX P/E vs Peers
Immunology and Inflammation Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $37B | 119.4 | - | +207% | |
| $11B | 30.4 | - | -19% | |
| $4B | 9.4Lowest | - | +68% | |
| $115B | 29.5 | 3.56 | +837%Best | |
| $8B | 26.8 | 1.17Best | -25% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ARGX Historical P/E Data (2024–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Dec 31 2025 | $840.95 | $31.24 | 26.9x | -48% |
| FY2025 Q2 | Jun 30 2025 | $551.22 | $15.07 | 36.6x | -30% |
| FY2024 Q4 | - | $615.00 | $6.67 | 92.2x | +78% |
Average P/E for displayed period: 51.9x
Full Stock Analysis
Deep dive into ARGX consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ARGX — Frequently Asked Questions
Quick answers to the most common questions about buying ARGX stock.
What is ARGX's P/E ratio?
argenx SE (ARGX) trailing twelve-month P/E ratio is 44.7x, based on TTM diluted EPS of $21.82. The 5-year average P/E is 51.9x and the historical range spans 26.9x to 92.2x.
Is ARGX stock overvalued or undervalued?
ARGX trades at 44.7x P/E, near its 5-year average of 51.9x. The 67th percentile ranking within the 26.9x–92.2x historical range places valuation within normal bounds.
Is ARGX stock expensive?
ARGX is fairly valued relative to its own history. The current P/E of 44.7x is near the 5-year average of 51.9x (67th percentile of historical range).
What is ARGX's historical P/E range?
Over the past 5 years, ARGX's P/E ratio has ranged from 26.9x to 92.2x, with a median of 36.6x and an average of 51.9x. The current P/E of 44.7x places the stock at the 67th percentile of this range. Full historical data spans 2024–2025.
How does ARGX's P/E compare to the S&P 500?
ARGX trades at 44.7x P/E versus the S&P 500 median of 24.4x. The 83% premium to the market typically reflects higher expected earnings growth or quality.
How does ARGX's valuation compare to Healthcare peers?
argenx SE P/E of 44.7x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ARGX's PEG ratio?
ARGX PEG ratio is N/A, based on a P/E of 44.7x and EPS growth of 53.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ARGX's earnings yield?
ARGX earnings yield is 2.24%, the inverse of its 44.7x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.